ISOPP publishes a whole host of information on biosimilars

Biosimilars/General | Posted 12/06/2020 post-comment0 Post your comment

The International Society of Oncology Pharmacy Practitioners (ISOPP) has published a whole host of information on biosimilars in a supplementary issue of the Journal of Oncology Pharmacy Practice.

22 AA010963

ISOPP ‘believes that oncology pharmacists have a crucial role to play’ when it comes to biosimilars. The group therefore set up a Task Force in 2018 with the aim of reviewing the available evidence and then to discuss the challenges and opportunities presented by the introduction of biosimilars into the oncology and supportive care setting and how these could be addressed.

As part of this initiative the ISOPP Task Force recently published its Publication on Biosimilars, which consists of the following four papers:

  • International Society of Oncology Pharmacy Practitioners Global Position on the Use of Biosimilars in Cancer Treatment and Supportive Care
  • Proceedings of the Biosimilars Workshop at International Symposium on Oncology Pharmacy Practice 2019 (ISOPP 2019)
  • Assessing Biosimilar Education Needs Among Oncology Pharmacy Practitioners Worldwide: An ISOPP Membership Survey
  • A Survey of Global Biosimilar Implementation Practice conducted by the International Society for Oncology Pharmacy Practitioners

The ISOPP global position statement is discussed in more detail in another GaBI Online article [1].

This Journal of Oncology Pharmacy Practice supplement represents the findings and educational resources generated by the Biosimilar Task Force to date. The ISOPP hopes ‘that these documents will facilitate the safe and effective use of biosimilars in clinical practice; and provide guidance and expertise to pharmacists around the world on the use of biosimilar products’.

Related articles
ESMO survey highlights need for education and alignment

Biosimilars education still needed for US and EU clinicians

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Oncology pharmacists issue position statement on biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jun 12]. Available from: www.gabionline.net/Biosimilars/General/Oncology-pharmacists-issue-position-statement-on-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: ISOPP

comment icon Comments (0)
Post your comment
Related content
Promotion of biosimilar product development in Puerto Rico
Biological 143606710 V14J14ct
Biosimilars/General Posted 17/10/2023
CVS’ Cordavis to launch Sandoz’s Hyrimoz (adalimumab)
15 AA010699
Biosimilars/General Posted 03/10/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010